This review examines the effect of targeting the insulin-like growth factor 1 receptor (IGF-IR) in human cancers. The results are disappointing. The causes for the failure are discussed, as well as the possible use of the IGF-IR as a secondary target. J. Cell. Physiol. 228: 675–679, 2013. © 2012 Wiley Periodicals, Inc.